Stellanin: a promising medical drug for accompanying therapy in lung cancer treatment
* Corresponding author
One of the cancer prevention measures involves the correction of the altered functions of the body's regulatory systems. Many malignant tumors are accompanied by the thyroid system dysfunction. The aim of our study was to reveal an effect of an iodine-containing drug on the development of a tumor process in the lungs and the level of thyroid hormones in blood and the thyroid gland in male rats.
Materials and Methods
Outbred white male rats were divided into the following groups: a group of intact animals (n=7); a comparison group – 5 weeks after an intravenous inoculation of sarcoma 45 (S45) at 2*106 (n=7); a main group – 5 weeks after an intravenous inoculation of S45 and intragastric administration of Stellanin at a single dose of 0.4 mg/kg within an hour after the inoculation (n=10). RIA was used to determine levels of free (F) and total triiodothyronine (T3) and thyroxine (T4) in the blood serum and the thyroid.
The lungs of rats in the comparison group were totally affected by the tumor, and the thyroid gland showed a sharp decrease in the levels of all hormone forms: T4 – by 18.7 times, T3 – by 8.5 times, FТ4 – by 8.1 times, FТ3 – by 21.3 times, while only FТ4 and FТ3 decreased in blood by 2.5 and 1.5 times, respectively (p<0.05). No tumor lesions were detected in the lungs of rats of the main group, and the hormone levels exceeded the levels in the comparison group: in the thyroid, FT4 by 3.7, T4 by 15.0 and T3 by 6.0 times; in blood, FT4 by 3.3 and FT3 by 1.7 times.
The effect of Stellanin inhibiting malignant growth of S45 in the lungs is accompanied by the restoration of low levels of thyroid hormones in the thyroid and blood.
Elena M. Frantsiyants, Irina V. Kaplieva, Valerija A. Bandovkina, Lidia K. Trepitaki, Ekaterina I. Surikova, Irina V. Neskubina, Julija A. Pogorelova, Natalia D. Cheryarina, Alla I. Shikhlyarova, Dmitriy A. Kharagezov, Stanislav G. Vlasov, Roza G. Luganskaya, Ekaterina S. Bosenko. Stellanin: a promising medical drug for accompanying therapy in lung cancer treatment. Cardiometry; Issue 20; November 2021; p.34-39; DOI: 10.18137/cardiometry.2021.20.3439; Available from: https://www.cardiometry.net/issues/no20-november-2021/stellanin-a-promising-medical